Funding for this research was provided by:
H2020 European Research Council (H2020- EINFRA-2015-1-675728, H2020-INFRAEDI-02-2018-823830)
Klaus Faber Foundation
Received: 6 March 2020
Accepted: 4 May 2020
First Online: 19 May 2020
Ethics approval and consent to participate
: The study was approved by the University Clinics Cologne (16-460).
: All study participants consent to publication.
: TB is an employee of AstraZeneca and has stock ownership and/or stock options or interests in the company.